AIM:ABC

Stock Analysis Report

Executive Summary

Abcam plc, a life sciences company, identifies, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the Americas, Europe, the Middle East, Africa, China, Japan, and the rest of Asia Pacific.

Snowflake

Fundamentals

Flawless balance sheet with moderate growth potential.

Risks

  • Abcam has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Abcam's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.6%

ABC

0.07%

GB Biotechs

0.4%

GB Market


1 Year Return

-16.4%

ABC

23.8%

GB Biotechs

-0.9%

GB Market

ABC underperformed the Biotechs industry which returned 23.8% over the past year.

ABC underperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -0.7% over the past year.


Share holder returns

ABCIndustryMarket
7 Day0.6%0.07%0.4%
30 Day-2.1%3.2%4.4%
90 Day-18.4%2.3%0.5%
1 Year-15.6%-16.4%24.8%23.8%3.9%-0.9%
3 Year45.1%40.7%12.0%10.1%20.5%6.1%
5 Year210.8%191.5%55.3%51.6%33.2%5.1%

Price Volatility Vs. Market

How volatile is Abcam's share price compared to the market and industry in the last 5 years?


Simply Wall St News

1 week ago | Simply Wall St

How Much Are Abcam plc (LON:ABC) Insiders Taking Off The Table?

Valuation

Is Abcam undervalued based on future cash flows and its price relative to the stock market?

53.37x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Abcam's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Abcam's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Abcam is overvalued based on earnings compared to the GB Biotechs industry average.

Abcam is overvalued based on earnings compared to the United Kingdom of Great Britain and Northern Ireland market.


Price Based on Expected Growth

Abcam is poor value based on expected growth next year.


Price Based on Value of Assets

Abcam is overvalued based on assets compared to the GB Biotechs industry average.


Next Steps

Future Growth

How is Abcam expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

16.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Abcam's revenue is expected to grow by 10.6% yearly, however this is not considered high growth (20% yearly).

Abcam's earnings are expected to grow by 16.6% yearly, however this is not considered high growth (20% yearly).

Abcam's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.

Abcam's earnings growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.

Abcam's earnings growth is expected to exceed the low risk savings rate of 1.2%.


Earnings per Share Growth Estimates


Future Return on Equity

Abcam is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Abcam performed over the past 5 years?

11.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Abcam's year on year earnings growth rate has been positive over the past 5 years.

Abcam's 1-year earnings growth is negative, it can't be compared to the 5-year average.

Abcam's 1-year earnings growth is negative, it can't be compared to the Europe Biotechs industry average.


Return on Equity

Abcam has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Abcam used its assets more efficiently than the GB Biotechs industry average last year based on Return on Assets.


Return on Capital Employed

Abcam has improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Abcam's financial position?


Financial Position Analysis

Abcam is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Abcam's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Abcam has no debt.

Abcam has not taken on any debt in the past 5 years.

Abcam has no debt, it does not need to be covered by operating cash flow.

Abcam has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Low level of unsold assets.

Abcam has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is Abcam's current dividend yield, its reliability and sustainability?

1.19%

Expected Dividend Yield


Upcoming Dividend Payment

Purchase Abcam before the 'Buy Limit' to receive their next dividend payment.


Dividend Yield and Payments Analysis

Abcam's pays a lower dividend yield than the bottom 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (2.02%).

Abcam's dividend is below the markets top 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (5.49%).

Abcam is not paying a notable dividend for United Kingdom of Great Britain and Northern Ireland, therefore no need to check if the payments are stable.

Abcam is not paying a notable dividend for United Kingdom of Great Britain and Northern Ireland, therefore no need to check if the payments are increasing.


Current Payout to Shareholders

No need to calculate the sustainability of Abcam's dividends as it is not paying a notable one for United Kingdom of Great Britain and Northern Ireland.


Future Payout to Shareholders

Dividends after 3 years are expected to be well covered by earnings (2.7x coverage).


Next Steps

Management

What is the CEO of Abcam's salary, the management and board of directors tenure and is there insider trading?

4.3yrs

Average management tenure


CEO

Alan Hirzel (51yo)

5yrs

Tenure

UK£1,788,000

Compensation

Mr. Alan Thomas Hirzel, BS, MS, MBA has been the Chief Executive Officer of Abcam Plc since September 8, 2014. Mr. Hirzel served as the Chief Marketing Officer of Abcam Plc from August 5, 2013 to September ...


CEO Compensation Analysis

Alan's remuneration is about average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.

Alan's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Management Age and Tenure

4.3yrs

Average Tenure

51yo

Average Age

The tenure for the Abcam management team is about average.


Board Age and Tenure

3.9yrs

Average Tenure

57.5yo

Average Age

The tenure for the Abcam board of directors is about average.


Insider Trading

More shares have been bought than sold by Abcam individual insiders in the past 3 months.


Recent Insider Transactions

BuyUK£28,92516 Sep 19
Gavin Hilary Wood
EntityIndividual
Role
Member of the Board of Directors
CFO & Executive Director
Shares2,500
Max PriceUK£11.57
BuyUK£12,62211 Sep 19
Louise A. V. Patten
EntityIndividual
Role
Lead Director
Senior Independent Director
Shares1,126
Max PriceUK£11.21
BuyUK£19,48311 Sep 19
Mara Aspinall
EntityIndividual
Role
Lead Director
Independent Non-Executive Director
Shares1,738
Max PriceUK£11.21
BuyUK£9,34911 Sep 19
Jonathan Milner
EntityIndividual
Role
Vice Chairman
Co-Founder & Non-Executive Deputy Chairman
Shares834
Max PriceUK£11.21
BuyUK£12,16311 Sep 19
Susan Harris
EntityIndividual
Role
Member of the Board of Directors
Independent Non-Executive Director
Shares1,085
Max PriceUK£11.21
BuyUK£49,54511 Sep 19
Alan Hirzel
EntityIndividual
Role
Chief Executive Officer
CEO & Executive Director
Shares4,350
Max PriceUK£11.39
BuyUK£1,990,57406 Dec 18
Jonathan Milner
EntityIndividual
Role
Vice Chairman
Co-Founder & Non-Executive Deputy Chairman
Shares187,790
Max PriceUK£10.60
SellUK£16,535,21402 Oct 18
Jonathan Milner
EntityIndividual
Role
Vice Chairman
Co-Founder & Non-Executive Deputy Chairman
Shares1,147,243
Max PriceUK£14.41
SellUK£370,45628 Sep 18
Suzanne Smith
EntityIndividual
Shares25,584
Max PriceUK£14.48
BuyUK£29,09428 Sep 18
Suzanne Smith
EntityIndividual
Shares2,011
Max PriceUK£14.47

Ownership Breakdown


Management Team

  • Mark Bushfield

    Senior Vice President of Research & Innovation

    • Tenure: 0yrs
  • Jonathan Milner (54yo)

    Co-Founder & Non-Executive Deputy Chairman

    • Tenure: 5yrs
    • Compensation: UK£70.00k
  • Alan Hirzel (51yo)

    CEO & Executive Director

    • Tenure: 5yrs
    • Compensation: UK£1.79m
  • Yvonne Chien

    Senior Vice President of Customer Experience

    • Tenure: 0yrs
  • Gavin Hilary Wood (49yo)

    CFO & Executive Director

    • Tenure: 3yrs
    • Compensation: UK£666.00k
  • Kirstie Speck

    Head of Consumer Insights

    • Tenure: 5.7yrs
  • Nick Skinner

    Senior Vice President of Human Resources

    • Tenure: 3.7yrs
  • James Staveley

    Vice President of Investor Relations

    • Tenure: 0yrs
  • Marc Perkins

    Interim Company Secretary

    • Tenure: 0.5yrs

Board Members

  • Giles F. Kerr (60yo)

    Non-Executive Director

    • Tenure: 0.8yrs
  • Lady Patten (65yo)

    Senior Independent Director

    • Tenure: 4.8yrs
    • Compensation: UK£129.00k
  • Peter Allen (63yo)

    Non-Executive Chairman

    • Tenure: 1.3yrs
    • Compensation: UK£9.00k
  • Mara Aspinall (57yo)

    Independent Non-Executive Director

    • Tenure: 1.8yrs
    • Compensation: UK£70.00k
  • Jonathan Milner (54yo)

    Co-Founder & Non-Executive Deputy Chairman

    • Tenure: 5yrs
    • Compensation: UK£70.00k
  • Alan Hirzel (51yo)

    CEO & Executive Director

    • Tenure: 5yrs
    • Compensation: UK£1.79m
  • Sue Harris (58yo)

    Independent Non-Executive Director

    • Tenure: 4.8yrs
    • Compensation: UK£70.00k
  • Gavin Hilary Wood (49yo)

    CFO & Executive Director

    • Tenure: 3yrs
    • Compensation: UK£666.00k

Company Information

Abcam plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Abcam plc
  • Ticker: ABC
  • Exchange: AIM
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£2.409b
  • Shares outstanding: 205.15m
  • Website: https://www.abcam.com

Number of Employees


Location

  • Abcam plc
  • Discovery Drive
  • Cambridge Biomedical Campus
  • Cambridge
  • Cambridgeshire
  • CB2 0AX
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ABCAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPNov 2005
ABCZ.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDNov 2005
A8C1DB (Deutsche Boerse AG)YesOrdinary SharesDEEURNov 2005
ABCZ.YOTCPK (Pink Sheets LLC)ADRUSUSDDec 2010

Biography

Abcam plc, a life sciences company, identifies, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the Americas, Europe, the Middle East, Africa, China ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/19 20:45
End of Day Share Price2019/09/19 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.